SCHEMBL4525619

SCHEMBL4525619

CC(C)(C)c1ccccc1N(CC(=O)Nc1ccc(-c2ccncc2)cc1)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 6/20 0.44
ROCK1 Q13464 6/20 0.44
SMN1; SMN2 Q16637 2/20 0.40
POLB P06746 2/20 0.40
STAT3 P40763 1/20 0.40
WNT3A P56704 1/20 0.40
NPC1 O15118 1/20 0.40
MITF O75030 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
HPGD P15428 1/20 0.40
NAMPT P43490 1/20 0.40
CYP17A1 P05093 1/20 0.40
LMNA P02545 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
NOTUM Q6P988 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4520971 0.83 ROCK2 (0.52) ROCK2ROCK1SMN1; SMN2POLBSTAT3
SCHEMBL4531740 0.80 ROCK2 (0.49) ROCK2ROCK1SMN1; SMN2POLBSTAT3
SCHEMBL4529314 0.79 ROCK2 (0.42) ROCK2ROCK1SMN1; SMN2POLBSTAT3
SCHEMBL4525610 0.79 CYP17A1 (0.49) ROCK2ROCK1SMN1; SMN2POLBSTAT3
SCHEMBL4535752 0.77 ROCK2 (0.51) ROCK2ROCK1SMN1; SMN2POLBSTAT3
SCHEMBL4533610 0.76 ROCK2 (0.48) ROCK2ROCK1SMN1; SMN2POLBSTAT3
SCHEMBL4518662 0.75 ROCK2 (0.47) ROCK2ROCK1SMN1; SMN2POLBSTAT3
SCHEMBL4534742 0.74 ROCK2 (0.51) ROCK2ROCK1SMN1; SMN2POLBSTAT3
SCHEMBL4525608 0.74 ROCK2 (0.46) ROCK2ROCK1SMN1; SMN2POLBSTAT3
SCHEMBL4526918 0.73 HPGD (0.46) ROCK2ROCK1SMN1; SMN2POLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211919-B2 Amide derivatives as rock inhibitors ASTELLAS PHARMA INC. (JP) 2012-07-03 US disclosed
US-20090105231-A1 AMIDE DERIVATIVES AS ROCK INHIBITORS ASTELLAS PHARMA INC. (JP) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105231-A1 AMIDE DERIVATIVES AS ROCK INHIBITORS ROCK1, ROCK2, RHOA ROCK2 2/4885ROCK1 1/4885SMN1; SMN2 3046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.